BTK Inhibitor With CAR T-Cell Therapy Deemed Effective in Relapsed/Refractory MCL
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
First-line bendamustine plus rituximab followed by ASCT and rituximab maintenance appears effective in mantle cell lymphoma.
Researchers sought to determine the treatment and survival trends for patients with mantle cell lymphoma.
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed that acalabrutinib 100 mg tablets were bioequivalent to the acalabrutinib 100 mg capsules.
ASCT as first-line treatment for patients with MCL appears to be underutilized in the US community setting.
Adding ibrutinib to standard chemoimmunotherapy improved the median progression-free survival by 2.3 years.
Researchers determined a combination of ibrutinib with rituximab appears to be effective in elderly patients with MCL.
The best overall response rate was 98%, and the complete response rate was 89%.
Incyte has withdrawn the NDA for parsaclisib for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.